УКР  |  ENG

Клинические исследования в Украине

Форум Пациентам

Исследования / № 00295750

Описание
Краткое названиеThe Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Полное названиеAn Open-Label, Multi-Centre, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT?® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
СпонсорFerring Pharmaceuticals
Industry
ИсточникFerring Pharmaceuticals
Под контролемUnited States: Food and Drug Administration
Yes
Краткое описаниеThe study was a three-arm, active-control, multi-centre, parallel group study.
СостояниеЗавершено
Дата началаFebruary 2006
ФазаPhase 3
Вид исследованияAllocation: Randomized, Control: Dose Comparison, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Набор0
КритерииMain Inclusion Criteria:

- Patients, aged 18 years or over, with histologically proven prostate cancer of all
stages in whom endocrine treatment is indicated.

- Baseline testosterone >1.5 ng/mL.

- Life expectancy of at least 12 months.
ПолMale
Минимальный возраст18 Years
Максимальный возрастN/A
УсловиеProstate Cancer
Применяемое лечение
DrugDegarelix
DrugDegarelix
DrugLeuprolide 7.5 mg
Контакты и расположение
Kiev , 2125Kiev City Clinical Hospital #3, Petr Ivaschenko 26, Petra Zaporogtsa str.
2011 © Клинические испытания в Украине